Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 5B 4.28B 4.01B 3.67B 6.89B 479B 6.98B 47.35B 18.46B 240B 18.79B 18.38B 795B P/E 2026 *
48x
P/E 2027 * 33.9x
Enterprise Value 4B 3.42B 3.2B 2.93B 5.5B 382B 5.57B 37.81B 14.74B 192B 15B 14.67B 635B EV / Sales 2026 *
3.14x
EV / Sales 2027 * 2.63x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day+1.58%
1 week+3.95%
Current month+14.03%
1 month+17.58%
3 months+40.81%
6 months+22.97%
Current year+10.45%
1 week 28.21
Extreme 28.21
30.96
1 month 24.23
Extreme 24.232
30.96
Current year 19.89
Extreme 19.89
30.96
1 year 19.69
Extreme 19.69
30.96
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 19/09/2024
Director of Finance/CFO 52 09/09/2021
Chief Tech/Sci/R&D Officer - 03/08/2025
Director TitleAgeSince
Director/Board Member 68 30/04/2008
Chairman 55 09/06/2016
Director/Board Member 73 24/11/2015
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Fiscal year

Chief Financial Officer

42,876 0.0250%
30/07/26 Sell

Chief Technology Officer

-16,558 0.0097%
06/02/26 Fiscal year

General Counsel

32,838 0.0194%
Change 5-day change 1-year change 3-year change Capi.($)
+1.58%+3.95%+18.28%+0.58% 5B
+1.09%+3.39%+3.50%+25.49% 51.22B
-1.07%+3.69%+479.26%+607.16% 45.38B
+1.44%+5.19%+21.06%+93.98% 41.97B
+1.47%+7.58%+35.29%+21.42% 42.15B
-0.93%-4.80%+17.39%+46.60% 31.95B
-0.60%+2.87% - - 16.73B
+1.32%+6.67%+33.29%+148.62% 17.1B
+0.03%+3.91%+5.84%+35.04% 14.76B
+1.28%+4.95%+84.98%+48.41% 13.91B
Average +0.56%+3.10%+77.65%+114.14% 28.02B
Weighted average by Cap. +0.49%+3.12%+101.67%+147.78%

Financials

2026 *2027 *
Net sales 1.27B 1.09B 1.02B 933M 1.75B 122B 1.77B 12.04B 4.69B 61.11B 4.78B 4.67B 202B 1.43B 1.23B 1.15B 1.05B 1.97B 137B 2B 13.54B 5.28B 68.76B 5.37B 5.26B 227B
Net income 106M 90.4M 84.55M 77.4M 145M 10.1B 147M 999M 389M 5.07B 396M 388M 16.77B 158M 136M 127M 116M 218M 15.14B 221M 1.5B 584M 7.6B 594M 581M 25.14B
Net Debt -1.01B -863M -807M -739M -1.39B -96.45B -1.41B -9.54B -3.72B -48.42B -3.78B -3.7B -160B -1.24B -1.06B -989M -906M -1.7B -118B -1.72B -11.69B -4.56B -59.35B -4.64B -4.54B -196B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
21/08/26 US$29.51 +1.62% 1,093,192
20/08/26 US$29.04 -3.87% 1,318,712
19/08/26 US$30.21 +0.10% 2,288,067
18/08/26 US$30.18 +4.03% 2,053,504
17/08/26 US$29.01 +2.73% 1,122,499
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
29.04USD
Average target price
33.85USD
Spread / Average Target
+16.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock